Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 17/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamifiban SCHEMBL871446 | 1.00 | ITGB3 (1.00) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL7282972 | 0.92 | ITGB3 (0.86) | ITGB3ITGA2BF2PRSS1 | |
| SCHEMBL7159286 | 0.91 | ITGB3 (0.83) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL7285135 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL7284586 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BCYP51A1CA1CA2 | |
| SCHEMBL8382276 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BCYP51A1CA1CA2 | |
| SCHEMBL7292028 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BF2PLGCYP51A1 | |
| SCHEMBL7284349 | 0.90 | ITGB3 (0.82) | ITGB3ITGA2BF2PLGCYP51A1 | |
| SCHEMBL13933091 | 0.90 | ITGB3 (0.83) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL8383672 | 0.89 | ITGB3 (0.80) | ITGB3ITGA2BCYP51A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2811 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| WO-2024087673-A1 | ANTIPLATELET DRUG AND PREPARATION METHOD, AND ANTIPLATELET DRUG CAPTURE AGENT | 中国科学院大学 | 2024-05-02 | — | — | WO | claimed |
| CN-115737814-A | Antiplatelet medicament, preparation method thereof and antiplatelet medicament capturing agent | 中国科学院大学 | 2023-03-07 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-10377779-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| CN-109893528-A | Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness | 福建医科大学 | 2019-06-18 | — | — | CN | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | claimed |
| US-20180086778-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. | 2018-03-29 | — | — | US | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0939900-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | Merck & Co., Inc. (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1999027962-A1 | USE OF A FIBRINOGEN RECEPTOR-ANTAGONIST FOR PREVENTING DISSEMINATED INTRAVASCULAR COAGULATION | WIEMANN GUNDULA (DE) | 1999-06-10 | — | — | WO | claimed |
| WO-1999019463-A1 | ANTICOAGULANT TEST | MERCK & CO., INC. (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1998022821-A1 | DETECTION OF ANTAGONIST-DEPENDENT GPIIb/IIIa RECEPTOR ANTIBODIES | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| WO-1998016204-A1 | PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-23 | — | — | WO | claimed |
| WO-1998011896-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIOVASCULAR DISEASE | MERCK & CO., INC. (US) | 1998-03-26 | — | — | WO | claimed |
| WO-1997035579-A1 | A METHOD FOR INHIBITING CLOT FORMATION | MERCK & CO., INC. (US) | 1997-10-02 | — | — | WO | claimed |
| EP-0505868-B1 | N-Acyl-alpha-aminoacids derivatives | HOFFMANN LA ROCHE (CH) | 1995-09-13 | — | — | EP | claimed |
| EP-0505868-A2 | N-Acyl-alpha-aminoacids derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-09-30 | — | — | EP | claimed |